An assessment of the impact of physico-chemical and biochemical characteristics on the human kinetic adjustment factor for systemic toxicants

Toxicology

Volumn 286, Issue 1-3, 2011, Pages 36-47

  Valcke, M ^a,b   Krishnan, K ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

Human kinetic adjustment factor (HKAF); Interindividual variability; Monte Carlo simulations; Phase I metabolism; Risk assessment; Steady state conditions; Toxicokinetics

Indexed keywords

ALFENTANIL; CEFTIZOXIME; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GENTAMICIN; THEOPHYLLINE; VANCOMYCIN;

ALGORITHM; ARTICLE; BLOOD; BODY HEIGHT; BODY WEIGHT; CLEARANCE; ENZYME METABOLISM; ENZYME SUBSTRATE; HUMAN KINETIC ADJUSTMENT FACTOR; KIDNEY CLEARANCE; LIVER; LIVER METABOLISM; LUNG CLEARANCE; MONTE CARLO METHOD; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PREGNANT WOMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STEADY STATE; TOXICOKINETICS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; COMPUTER SIMULATION; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; ENVIRONMENTAL POLLUTANTS; FEMALE; HUMANS; INFANT, NEWBORN; INHALATION EXPOSURE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PHARMACOKINETICS; PREGNANCY; RISK ASSESSMENT;

EID: 79959223930     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.05.003     Document Type: Article

References (86)

1. Andersen M.E. A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: analysis at steady state. Toxicol. Appl. Pharmacol. 1981, 60:509-526.
2. Asbury W.H., Darsey E.H., Rose W.B., Murphy J.E., Buffington D.E., Capers C.C. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann. Pharmacother. 1993, 27:490-496.
3. Bachmann K., Jauregui L., Sides G., Sullivan T.J. Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin. J. Clin. Pharmacol. 1993, 33:861-865.
4. Bachmann K., Nunlee M., Martin M., Sullivan T., Jauregui L., DeSante K., Sides G.D. Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin. J. Clin. Pharmacol. 1990, 30:1001-1005.
5. Bjorkman S. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models. J. Pharmacokinet. Pharmacodyn. 2003, 30:285-307.
6. Bjorkman S., Redke F. Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application to prediction of clearance in man. J. Pharm. Pharmacol. 2000, 52:1065-1074.
7. Borin M.T., Hughes G.S., Spillers C.R., Patel R.K. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil. Antimicrob. Agents Chemother. 1990, 34:1094-1099.
8. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameters values for physiologically based pharmacokinetic models. Toxicol. Ind. Health. 1997, 13:407-484.
9. Clewell H.J., Gentry P.R., Covington T.R., Sarangapani R., Teeguarden J.G. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 2004, 79:381-393.
10. Clewell H.J., Gentry P.R., Gearhart J.M., Covington T.R., Banton M.I., Andersen M.E. Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicol. Sci. 2001, 63:160-172.
11. Corley R.A., Bartels M.J., Carney E.W., Weitz K.K., Soelberg J.J., Gies R.A., Thrall K.D. Development of a physiologically based pharmacokinetic model for ethylene glycol and its metabolite, glycolic Acid, in rats and humans. Toxicol. Sci. 2005, 85:476-490.
12. Corley R.A., Bormett G.A., Ghanayem B.I. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. Toxicol. Appl. Pharmacol. 1994, 129:61-79.
13. Csanady G.A., Filser J.G. The relevance of physical activity for the kinetics of inhaled gaseous substances. Arch. Toxicol. 2001, 74:663-672.
14. Davy M., Allen A., Bird N., Rost K.L., Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. Chemotherapy 1999, 45:478-484.
15. DeWoskin R.S., Thompson C.M. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul. Toxicol. Pharmacol. 2008, 51:66-86.
16. Dorne J.L., Renwick A.G. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol. Sci. 2005, 86:20-26.
17. Dorne J.L., Walton K., Renwick A.G. Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food Chem. Toxicol. 2001, 39:1153-1173.
18. Dorne J.L., Walton K., Renwick A.G. Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates. Food Chem. Toxicol. 2001, 39:681-696.
19. Dorne J.L., Walton K., Renwick A.G. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem. Toxicol. 2003, 41:201-224.
20. Dorne J.L., Walton K., Renwick A.G. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. Food Chem. Toxicol. 2003, 41:225-245.
21. Dorne J.L., Walton K., Renwick A.G. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). Food Chem. Toxicol. 2004, 42:397-421.
22. Dorne J.L., Walton K., Renwick A.G. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment. Food Chem. Toxicol. 2004, 42:275-298.
23. Dorne J.L., Walton K., Renwick A.G. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem. Toxicol. 2005, 43:203-216.
24. Dorne J.L., Walton K., Slob W., Renwick A.G. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?. Food Chem. Toxicol. 2002, 40:1633-1656.
25. Dourson M.L., Felter S.P., Robinson D. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 1996, 24(2 Pt 1):108-120.
26. Dourson M.L., Stara J.F. Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 1983, 3:224-238.
27. Ehrnebo M., Agurell S., Jalling B., Boreus L.O. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur. J. Clin. Pharmacol. 1971, 3:189-193.
28. Faustman E.M., Ribeiro P. Pharmacokinetic consideration in developmental toxicity. Developmental Toxicology: Risk Assessment and the Future 1990, 109-136. Van Nostrand Reinhold, New York, NY. R.D. Hood (Ed.).
29. Gentry P.R., Hack C.E., Haber L., Maier A., Clewell H.J. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol. Sci. 2002, 70:120-139.
30. Giacoia G., Jusko W.J., Menke J., Koup J.R. Theophylline pharmacokinetics in premature infants with apnea. J. Pediatr. 1976, 89:829-832.
31. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker Inc., New York, NY. second ed.
32. Ginsberg G., Hattis D., Russ A., Sonawane B. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J. Toxicol. Environ Health A 2004, 67:297-329.
33. Ginsberg G., Hattis D., Sonawane B., Russ A., Banati P., Kozlak M., Smolenski S., Goble R. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 2002, 66:185-200.
34. Ginsberg G., Perkovich Foos B., Firestone M.P. Review and analysis of inhalation dosimetry methods for application to children's risk assessment. J. Toxicol. Environ Health A 2005, 68:573-615.
35. Gonzalez M.A., Kisicki J., Straughn A.B. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system. Clin. Ther. 1994, 16:686-692.
36. Gotz J., Sauter R., Steinijans V.W., Jonkman J.H. Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily. Int. J. Clin. Pharmacol. Ther. 1994, 32:168-173.
37. Healy D.P., Polk R.E., Garson M.L., Rock D.T., Comstock T.J. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob. Agents Chemother. 1987, 31:393-397.
38. ICRP Annals of the ICRP, ICRP Publication 89. Ann ICRP. 2002, 32:5-265.
39. IPCS, 1994. Assessing human health risks of chemicals: derivation of guidance values for health based exposure limits. World Health Organization, International Panel on Chemical Safety. Environmental Health Criteria. Geneva.
40. IPCS, 2005. Chemical-Specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability: Guidance Document for the Use of Data in Dose/Concentration-Response Assessment. WHO/IPCS/01.4, 1-96. International Panel on Chemical Safety, World Health Organisation, Geneva, Switzerland.
41. Johnson T.N., Rostami-Hodjegan A., Tucker G.T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 2006, 45:931-956.
42. Johnsrud E.K., Koukouritaki S.B., Divakaran K., Brunengraber L.L., Hines R.N., McCarver D.G. Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther. 2003, 307:402-407.
43. Jonkman J.H., Sollie F.A., Sauter R., Steinijans V.W. The influence of caffeine on the steady-state pharmacokinetics of theophylline. Clin. Pharmacol. Ther. 1991, 49:248-255.
44. Kawajiri K., Hayashi S.I. The CYP1 family. Cytochrome P450 Metabolic and Toxicological Aspects 1996, 77-98. CRC Press, Boca Raton. C. Ioannides (Ed.).
45. Kildoo C.W., Lin L.M., Gabriel M.H., Folli H.L., Modanlou H.D. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev. Pharmacol. Ther. 1989, 14:77-83.
46. Krishnan K., Loizou G.D., Spendiff M., Lipscomb J.C., Andersen M.E. PBPK modeling: a primer. Quantitative Modeling in Toxicology 2010, 21-58. John Wiley and Sons Ltd., West Sussex. M.E. Krishnan, M.E. Andersen (Eds.).
47. Kusama M., Yamamoto K., Yamada H., Kotaki H., Sato H., Iga T. Effect of cilastatin on renal handling of vancomicina in rats. J. Pharm. Sci. 1998, 87:1173-1176.
48. Lacroix D., Sonnier M., Moncion A., Cheron G., Cresteil T. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem. 1997, 247:625-634.
49. Landers S., Berry P.L., Kearns G.L., Kaplan S.L., Rudolph A.J. Gentamicin disposition and effect on development of renal function in the very low birth weight infant. Dev. Pharmacol Ther. 1984, 7:285-302.
50. Lapare S., Tardif R., Brodeur J. Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. I. Toluene and m-xylene. Int. Arch. Occup. Environ. Health. 1993, 64:569-580.
51. Lapare S., Tardif R., Brodeur J. Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. II. 1,1,1-Trichloroethane and trichloroethylene. Int. Arch. Occup. Environ. Health. 1995, 67:375-394.
52. Lipscomb J.C., Poet T.S. In vitro measurments of metabolism for application in pharmacokinetic modeling. Pharmacol. Ther. 2008, 118:82-103.
53. Lipscomb J.C., Teuschler L.K., Swartout J., Swan G.E., Snawder J.E. Variance of microsomal protein and cytochrome P450 2E1 and 3A forms in adult human liver. Toxicol. Mech. Method 2003, 13:45-51.
54. Malviya S., Lerman J. The blood/gas solubilities of sevoflurane, isoflurane, halothane and serum constituent concentrations in neonates and adults. Anesthesiology 1990, 72:793-796.
55. Meek M.E., Renwick A., Ohanian E., Dourson M., Lake B., Naumann B.D., Vu V. Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. Toxicology 2002, 181-182:115-120.
56. Meistelman C., Saint-Maurice C., Lepaul M., Levron J.C., Loose J.P., Mac G.K. A comparison of alfentanil pharmacokinetics in children and adults. Anesthesiology 1987, 66:13-16.
57. Naumann B.D., Silverman K.C., Dixit R., Faria E.C., Sargent E.V. Case studies for categorical data-derived adjustment factors. Hum. Ecol. Risk Assess. 2001, 7:61-105.
58. Nelson W.E. Textbook of Pediatrics 1991, W.B. Sauders Company, New York.
59. Nong A., Krishnan K. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach. Regul. Toxicol. Pharmacol. 2007, 48:93-101.
60. Nong A., McCarver D.G., Hines R.N., Krishnan K. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol. 2006, 214:78-87.
61. Pelekis M., Gephart L.A., Lerman S.E. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul. Toxicol. Pharmacol. 2001, 33:12-20.
62. Pelekis M., Krewski D., Krishnan K. Physiologically based algebraic expressions for predicting steady-state toxicokinetics of inhaled vapors. Toxicol. Method 1997, 7:205-225.
63. Pelekis M., Krishnan K. Magnitude and mechanistic determinants of the interspecies toxicokinetic uncertainty factor for organic chemicals. Regul. Toxicol. Pharmacol. 2004, 40:264-271.
64. Pelekis M., Nicolich M.J., Gauthier J.S. Probabilistic framework for the estimation of the adult and child toxicokinetic intraspecies uncertainty factors. Risk Anal. 2003, 23:1239-1255.
65. Poulin P., Krishnan K. A mechanistic algorithm for predicting blood:air partition coefficients of organic chemicals with the consideration of reversible binding in hemoglobin. Toxicol. Appl. Pharmacol. 1996, 136:131-137.
66. Price K., Haddad S., Krishnan K. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ Health A 2003, 66:417-433.
67. Price P.S., Conolly R.B., Chaisson C.F., Gross E.A., Young J.S., Mathis E.T., Tedder D.R. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 2003, 33:469-503.
68. Reinhardt D., Berdel D., Heimann G., Kusenbach G., Von B.A., Johnson E., Steinijans V.W., Staudinger H. Steady state pharmacokinetics, metabolism and pharmacodynamics of theophylline in children after unequal twice-daily dosing of a new sustained-release formulation. Chronobiol. Int. 1987, 4:369-380.
69. Ronis M.J.J., Lindros K.O., Ingelman-Sundberg M. The CYP2E family. Cytochrome P450 Metabolic and Toxicological Aspects 1996, 211-240. CRC Press, Boca Raton. C. Ioannides (Ed.).
70. Rosen J.P., Danish M., Ragni M.C., Saccar C.L., Yaffe S.J., Lecks H.I. Theophylline pharmacokinetics in the young infant. Pediatrics 1979, 64:248-251.
71. Saarenmaa E., Neuvonen P.J., Fellman V. Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. J. Pediatr. 2000, 136:767-770.
72. Santeiro M.L., Christie J., Stromquist C., Torres B.A., Markowsky S.J. Pharmacokinetics of continuous infusion fentanyl in newborns. J. Perinatol. 1997, 17:135-139.
73. Sarangapani R., Gentry P.R., Covington T.R., Teeguarden J.G., Clewell H.J. Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal. Toxicol. 2003, 15:987-1016.
74. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270:414-423.
75. Simons F.E., Simons K.J. Pharmacokinetics of theophylline in infancy. J. Clin. Pharmacol. 1978, 18:472-476.
76. Sonnier M., Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J. Biochem. 1998, 251:893-898.
77. Statistics Canada, 2003. Canadian community health survey, cycle 2.1. Last accessed: February 1, 2010. http://www.statcan.gc.ca/cgi-bin/imdb/p2SV.pl%3FFunction=getSurvey%26SurvId=3226%26SurvVer=0%26SDDS=3226%26InstaId=15282%26InstaVer=2%26lang=en%26db=imdb%26adm=8%26dis=2.
78. Thomas R.S., Bigelow P.L., Keefe T.J., Yang R.S. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. Am. Ind. Hyg. Assoc. J. 1996, 57:23-32.
79. U.S.EPA, 2002. A review of the reference dose and reference concentration process. Risk Assessment Forum. EPA/630/P-02/00F. Washington, DC.
80. U.S.EPA, 2004. Toxicological Review of Boron and Compounds. Integrated Risk Information System (IRIS). EPA 634/04/052. Washington DC, U.S. Environmental Protection Agency.
81. Veulemans H., Masschelein R. Experimental human exposure to toluene.II. Toluene in venous blood during and after exposure. Int. Arch. Occup. Environ Health. 1978, 42:105-117.
82. Valcke M., Krishnan K. Physiologically based pharmacokinetic modeling in the risk assessment of developmental toxicants. Developmental Toxicology 2009, 243-274. Informa Health Care, New York. D.K. Hansen, B.D. Abbott (Eds.).
83. Valcke M., Krishnan K. Evaluation of the impact of the exposure route on the human kinetic adjustment factor. Regul. Toxicol. Pharmacol. 2011, 59:258-269. 10.1016/j.yrtph.2010.10.008.
84. Vincent J., Teng R., Dogolo L.C., Willavize S.A., Friedman H.L. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J. Antimicrob. Chemother. 1997, 39(Suppl. B):81-86.
85. Wang Y., Moss J., Thisted R. Predictors of body surface area. J. Clin. Anesth. 1992, 4:4-10.
86. Winter M.E. Basic Clinical Pharmacokinetics 2010, Lippincott Williams and Wilkins, Baltimore, MD. fifth ed.